MESO vs. QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, BPMC, TLX, and ELAN
Should you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.
Mesoblast vs.
Mesoblast (NASDAQ:MESO) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership.
Mesoblast received 163 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 70.31% of users gave Mesoblast an outperform vote while only 60.29% of users gave Qiagen an outperform vote.
Qiagen has higher revenue and earnings than Mesoblast.
Mesoblast currently has a consensus price target of $18.00, indicating a potential upside of 4.47%. Qiagen has a consensus price target of $47.71, indicating a potential upside of 23.72%. Given Qiagen's higher probable upside, analysts clearly believe Qiagen is more favorable than Mesoblast.
In the previous week, Qiagen had 8 more articles in the media than Mesoblast. MarketBeat recorded 12 mentions for Qiagen and 4 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.68 beat Qiagen's score of -0.25 indicating that Mesoblast is being referred to more favorably in the media.
1.4% of Mesoblast shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Qiagen has a net margin of 4.23% compared to Mesoblast's net margin of 0.00%. Qiagen's return on equity of 13.92% beat Mesoblast's return on equity.
Mesoblast has a beta of 3.37, meaning that its stock price is 237% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.
Summary
Qiagen beats Mesoblast on 9 of the 17 factors compared between the two stocks.
Get Mesoblast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mesoblast Competitors List
Related Companies and Tools
This page (NASDAQ:MESO) was last updated on 2/21/2025 by MarketBeat.com Staff
Free MESO Stock Alerts